Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Omega-3 fatty acids for bipolar disorder
Your Article Summary
See Latest ArticlesThe ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease
International Journal of Geriatric Psychiatry, 06/30/09
A 4-point ADAS-cog change at 6 months is clinically meaningful for groups. Substantial individual misclassification between the ADAS-cog and clinical measures suggests no inherent meaning to a 4-point ADAS-cog change for a given patient.
Methods- Secondary analysis of the video imaging synthesis of treating Alzheimer's disease (VISTA) study: a 4-month, multi-centre, parallel-group, double-blind, placebo-controlled, trial of galantamine in 130 mild-moderate Alzheimer's disease patients (4-month open-label follow-up).
- ADAS-cog responses at 6 months were compared with outcomes on three clinical measures: clinician's interview based impression of change-plus caregiver input (CIBIC+), patient/carer-goal attainment scaling (PGAS) and clinician-GAS (CGAS).
- Thirty-seven of 99 patients improved by 4 points on the ADAS-cog at 6 months, and 16/99 showed 4-point worsening.
- ADAS-cog change scores correlated notionally to modestly with changes on the CGAS (r = -0.31), the PGAS (r = -0.29) and the CIBIC+ (r = 0.31).
- As a group, patients with ADAS-cog improvement were significantly more likely to improve on the clinical measures; those who worsened showed non-significant clinical decline.
- Individually, about half were misclassified in relation to each clinical measure; often when the ADAS-Cog detected no change, clinically meaningful effects could be detected. Even so, no ADAS-Cog cut-point optimally classified patients' clinical responses.
Today in Child/Adolescent Psych...keeping you current
Receive free subspecialty "5-minute updates" via email
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
JAMA, 10/28/09
A Double-Blind, Randomized, Placebo-Controlled Study of Fixed-Dose Aripiprazole in Children and Adolescents With Autistic Disorder
Journal of the American Academy of Child and Adolescent Psychiatry, 10/06/09
How adolescents who cut themselves differ from those who take overdoses
European Child and Adolescent Psychiatry, 10/05/09
Today in Geriatric Psych...keeping you current
Receive free subspecialty "5-minute updates" via email
Management of agitation and aggression associated with Alzheimers disease: controversies and possible solutions
Current Opinion in Psychiatry, 10/12/09
Green tea consumption is associated with depressive symptoms in the elderly
American Journal of Clinical Nutrition, 10/15/09
Memantine: a review of studies into its safety and efficacy in treating Alzheimer’s disease and other dementias
Clinical Interventions in Aging, 09/29/09
Sponsor
Article Search
Sponsor